Literature DB >> 8934581

Drug-induced tinnitus and other hearing disorders.

H Seligmann1, L Podoshin, J Ben-David, M Fradis, M Goldsher.   

Abstract

Tinnitus and hearing loss, both reversible and irreversible, are associated both with acute intoxication and long term administration of a large range of drugs. The mechanism causing drug-induced ototoxicity is unclear, but may involve biochemical and consequent electrophysiological changes in the inner ear and eighth cranial nerve impulse transmission. Over 130 drugs and chemicals have been reported to be potentially ototoxic. The major classes are the aminoglycosides and other antimicrobials, anti-inflammatory agents, diuretics, antimalarial drugs, antineoplastic agents and some topically administered agents. Prevention of drug-induced ototoxicity is generally based upon consideration and avoidance of appropriate risk factors, as well as on monitoring of renal function, serum drug concentrations, and cochlear and auditory functions before and during drug therapy. Ototoxicity, although not life-threatening, may cause considerable discomfort to patients taking ototoxic drugs, and in some cases drug discontinuation may be necessary to prevent permanent damage. Much research has been performed to investigate the causes and mechanisms of ototoxicity, to try to prevent this complication. Despite these efforts, ototoxicity still occurs, and there is much work to be done in order to understand the mechanism of ototoxicity of different drugs and to prevent hearing loss and tinnitus in the future.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8934581     DOI: 10.2165/00002018-199614030-00006

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  133 in total

1.  Clinical perspectives on ototoxic drugs.

Authors:  G J Matz
Journal:  Ann Otol Rhinol Laryngol Suppl       Date:  1990-06

2.  Drug-induced deafness.

Authors: 
Journal:  JAMA       Date:  1973-04-23       Impact factor: 56.272

3.  Relative efficacy of indomethacin and acetylsalicylic acid in rheumatoid arthritis.

Authors:  R S Pinals; S Frank
Journal:  N Engl J Med       Date:  1967-03-02       Impact factor: 91.245

4.  Meniere-like syndrome following epidural morphine analgesia.

Authors:  S Linder; A Borgeat; J Biollaz
Journal:  Anesthesiology       Date:  1989-11       Impact factor: 7.892

Review 5.  Drugs affecting the inner ear. A review of their clinical efficacy, mechanisms of action, toxicity, and place in therapy.

Authors:  C H Norris
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

6.  Sudden hearing loss in a cyclosporin-treated renal transplantation patient.

Authors:  T Arinsoy; T Akpolat; M Ataman; N Arik; C Sungur; U Yasavul; C Turgan; S Caglar
Journal:  Nephron       Date:  1993       Impact factor: 2.847

7.  Ototoxicity with azithromycin.

Authors:  M R Wallace; L K Miller; M T Nguyen; A R Shields
Journal:  Lancet       Date:  1994-01-22       Impact factor: 79.321

Review 8.  Ototoxic liability of erythromycin and analogues.

Authors:  R E Brummett
Journal:  Otolaryngol Clin North Am       Date:  1993-10       Impact factor: 3.346

Review 9.  Ototoxicity associated with salicylates. A brief review.

Authors:  J A Brien
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

10.  Erythromycin ototoxicity: analysis and conclusions based on 22 case reports.

Authors:  R C Haydon; J W Thelin; W E Davis
Journal:  Otolaryngol Head Neck Surg       Date:  1984-12       Impact factor: 3.497

View more
  24 in total

Review 1.  Impact of nonaspirin nonsteroidal anti-inflammatory agents and acetaminophen on sensorineural hearing loss: a systematic review.

Authors:  Meghann E Kyle; James C Wang; Jennifer J Shin
Journal:  Otolaryngol Head Neck Surg       Date:  2015-01-05       Impact factor: 3.497

2.  A case of asenapine-induced tinnitus.

Authors:  Poonam S Joshi; Ashish Sharma
Journal:  Prim Care Companion CNS Disord       Date:  2012-07-05

3.  Comparison of the protective efficacy between intratympanic dexamethasone and resveratrol treatments against cisplatin-induced ototoxicity: an experimental study.

Authors:  Gökçe Simsek; Burak Mustafa Taş; Nuray Bayar Muluk; Musa Azman; Rahmi Kılıç
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-09-17       Impact factor: 2.503

4.  Natural Compounds as Occult Ototoxins? Ginkgo biloba Flavonoids Moderately Damage Lateral Line Hair Cells.

Authors:  Sarah Neveux; Nicole K Smith; Anna Roche; Bruce E Blough; Wimal Pathmasiri; Allison B Coffin
Journal:  J Assoc Res Otolaryngol       Date:  2016-11-28

5.  PHARMACOLOGICAL TREATMENTS FOR TINNITUS: NEW AND OLD.

Authors:  R Salvi; E Lobarinas; W Sun
Journal:  Drugs Future       Date:  2009       Impact factor: 0.148

6.  Development and validation of a cisplatin dose-ototoxicity model.

Authors:  Marilyn F Dille; Debra Wilmington; Garnett P McMillan; Wendy Helt; Stephen A Fausti; Dawn Konrad-Martin
Journal:  J Am Acad Audiol       Date:  2012 Jul-Aug       Impact factor: 1.664

7.  Effect of interferon treatment on hearing of patients with chronic hepatitis C.

Authors:  Abdulrahman Hagr; Dima Jamjoom; Faisal M Sanai; Waleed Al Hamoudi; Ayman A Abdo; Ahmed Al-Arfaj
Journal:  Saudi J Gastroenterol       Date:  2011 Mar-Apr       Impact factor: 2.485

8.  High systemic gentamicin levels and ototoxicity after implantation of gentamicin beads in a 70-year-old man--a case report.

Authors:  Paul A G de Klaver; Jan de Koning; Rob P A Janssen; Luc J J Derijks
Journal:  Acta Orthop       Date:  2009-12       Impact factor: 3.717

9.  High-frequency sensorineural hearing loss in patients with ankylosing spondylitis: is it an extrarticuler feature of disease?

Authors:  Mehmet Adam; Alper Nabi Erkan; Didem Arslan; Berrin Leblebici; Levent Ozlüoğlu; M Nafiz Akman
Journal:  Rheumatol Int       Date:  2007-09-26       Impact factor: 2.631

10.  Using the zebrafish lateral line to screen for ototoxicity.

Authors:  Lynn L Chiu; Lisa L Cunningham; David W Raible; Edwin W Rubel; Henry C Ou
Journal:  J Assoc Res Otolaryngol       Date:  2008-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.